Consumer Defensive

Covista Inc. (CVSA)

$4.2B
Market Cap
17.0
P/E Ratio
0.73
Beta
Dividend Yield
Piotroski 7/9Altman Z 4.3 SafeBeneish M -2.47 CleanROIC−WACC +3.3%

Quantitative Summary

Deterministic

At 17.0x earnings — a 48% discount to the sector average of 32.6x — CVSA is in the lower valuation range. Financial health metrics are strong: Piotroski 7/9, Altman Z 4.3 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of this consumer defensive operator demonstrate a robust spread between capital efficiency and cost of equity, with an ROIC-WACC margin of +3.3% indicating value creation above the hurdle rate. The DuPont decomposition reveals that earnings quality is primarily driven by exceptional profitability rather than leverage or asset turnover; specifically, a net margin of 13.3% sits atop a commanding gross margin of 56.9%, suggesting strong pricing power within its niche. Financial integrity metrics further support this profile: the high Piotroski F-Score of 7/9 signals improving fundamentals and balance sheet strength, while an Altman Z-Score of 4.3 places the firm in a safe zone away from distress. Conversely, the Beneish M-Score of -2.47 indicates low probability of earnings manipulation, reinforcing confidence in the reported margins despite the company's small market capitalization relative to its sector peers.

Valuation metrics present a significant divergence between current pricing and intrinsic value estimates derived from discounted cash flow models. While the stock trades at a P/E multiple of 17.0x—substantially below the sector average of 33.9x—the DCF analysis implies a fair value of $145, suggesting the market may be underweighting future growth potential or assigning excessive risk to this specific name. The revenue growth trajectory of 12.8% YoY aligns with the implied growth assumptions required to justify such a wide gap between current multiples and theoretical fair value, yet the discount relative to peers warrants scrutiny regarding whether macro headwinds are being over-penalized in the share price or if structural barriers limit scalability compared to larger competitors.

Risk assessment highlights an asymmetric profile where downside protection appears anchored by strong profitability metrics, though liquidity constraints inherent to small-cap status remain a latent variable not captured in standard valuation models. The combination of high margins and clean earnings quality provides a defensive floor, but the absence of leverage benefits means ROE is sensitive to any erosion in operating efficiency or margin compression. Investors must weigh whether the current discount reflects temporary sentiment-driven dislocation or persistent structural challenges that could prevent the realization of the $145 fair value target.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →6.8%8.8%10.8%
2%$185$126$94
3%$230$145$104
4%$307$172$117

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=8.8%, terminal growth 3%. Fair value $145 (+0.0%). Not investment advice.

Valuation Context

17.0x
CVSA P/E
32.6x
Sector Avg
-48%
vs Sector

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
4.3
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.47
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

56.9%
Gross Margin
13.3%
Net Margin
12.1%
ROIC
8.8%
WACC
ROIC − WACC Spread: +3.3%— Positive spread.
+12.8%
Revenue Growth (YoY)
+73.3%
Earnings Growth (YoY)
287.6M
Free Cash Flow

Balance Sheet Health

0.92x
Debt / Equity
0.82x
Current Ratio
7.7x
Interest Coverage
0.8x
Net Debt / EBITDA
6.34%
FCF Yield
427.3M
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $1.65
Act: $1.92
+16.2%
Q3
✓ Beat
Est: $1.53
Act: $1.66
+8.3%
Q2
✓ Beat
Est: $1.58
Act: $1.75
+10.9%
Q1
✓ Beat
Est: $2.19
Act: $2.43
+11.1%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

13.1
Forward P/E
PEG Ratio
2.89
Price/Book
438159
Avg Volume
$156.26
52W High
$86.97
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$138M
Tracked Passive Exposure
7
ETFs Holding CVSA
0.12%
Avg Weight in ETFs
$113B
Total ETF AUM

When investors buy or sell ETFs like SLYG or SPSM, the fund manager is mechanically forced to buy or sell CVSA shares regardless of Covista Inc.'s individual fundamentals. We estimate $138M of passive capital is structurally linked to CVSA through 7 tracked ETFs. Passive flows have a limited but growing influence on CVSA's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 7 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in Covista Inc. to visualize passive redemption contagion across ETFs and collateral stocks.

CVSA Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
CVSAEpicenterVBRETFVTWOETFSPSMETFAMZNLow RiskTSLALow RiskHDLow RiskTJXLow RiskMCDLow Risk
CVSA Price Drop (%)0

If Covista Inc. (CVSA) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Amazon.com Inc. (AMZN) as the most exposed collateral stock, sharing 1 ETFs with CVSA. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 7 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

CVSA Ownership Dynamics

Ticker
CVSA

Float lock-up computed from 7 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

CVSA Capital Efficiency

How efficiently does Covista Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$288M
EBITDA
$427M
FCF Conversion
67%
Reinvestment Rate
33%
67% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
12.1%
ROIC − WACC Spread
3.3%

Covista Inc. converts 67% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 3.3% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-12200$130.23$26,046
2026-05-1129,432$133.73$3.9M
2026-04-274$107.63$430.52
2026-04-20100$117.91$11,791
2026-04-064$117.90$471.6
2026-03-31673$114.03$76,742.19
2026-03-233$106.49$319.47
2026-03-202$106.98$213.96
2026-03-135,254$103.84$545,575.36
2026-03-10509$103.13$52,493.17
2026-03-09109$102.05$11,123.45
2026-03-049,070$102.70$931,489
2026-02-27315$98.76$31,109.4
2026-02-25969$99.59$96,502.71

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare CVSA to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.